Compass Therapeutics Investor Presentation Deck

CTX-009 Interim Phase 2 Study Summary 24 patients with BTC have been enrolled and dosed 10 partial responses (PRs) for a 37.5% ORR in patients treated in the second- and third-line settings (64% ORR of patients treated in the 2nd line setting) Median PFS 9.4 months Median OS 12.5 months Adverse event profile similar to Phase 1 studies COMPASS THERAPEUTICS Other regimens in BTC FOLFOX (NCCN guidelines): 5% ORR in the second-line setting 4.0 month median PFS 6.2 month median OS TOPAZ-1 (Phase 3 study): 26.7% ORR for Gem/Cis/Durvalumab (anti PD-L1) in the first-line setting 23

View entire presentation